Ovarian cancer cells treated with CCL5 showed decreased apoptosis when exposed to cisplatin, which was consistent with the finding that platinum-resistant patient samples expressed elevated CCL5 levels compared to platinum-sensitive samples. This evidence concerns the gene CCL5 and ovarian carcinoma.